Panacea Biotec (BOM:531349) Long-Term Debt: ₹0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:531349 Panacea Biotec Ltd BOM:531349
59 GF Score
Price ₹402.75
GF Value ₹403.16
Valuation Fairly Valued
View Full Analysis

What is Panacea Biotec Long-Term Debt?

Panacea Biotec BOM:531349 -0.85% 59 Long-Term Debt is ₹0 Mil as of Jun. 2026. GuruFocus rates BOM:531349 with a GF Score™ of 59/100 and a GF Value™ of ₹403.16 (Fairly Valued).

Panacea Biotec's Long-Term Debt for the quarter that ended in Jun. 2026 was ₹0 Mil.

Panacea Biotec's quarterly Long-Term Debt increased from Dec. 2025 (₹0 Mil) to Mar. 2026 (₹237 Mil) but then declined from Mar. 2026 (₹237 Mil) to Jun. 2026 (₹0 Mil).

Panacea Biotec's annual Long-Term Debt stayed the same from Mar. 2024 (₹150 Mil) to Mar. 2025 (₹150 Mil) but then increased from Mar. 2025 (₹150 Mil) to Mar. 2026 (₹237 Mil).

Panacea Biotec  (BOM:531349) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Panacea Biotec Long-Term Debt Related Terms

Panacea Biotec Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Panacea Biotec's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Panacea Biotec Long-Term Debt Chart

Panacea Biotec Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 341.03 201.64 150.00 150.00 236.60

Panacea Biotec Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 229.00 0.00 236.60 0.00
BOM:531349
59GF Score
Panacea Biotec Ltd BOM:531349
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of ₹0 Mil mean?
Panacea Biotec (BOM:531349) has a Long-Term Debt of ₹0 Mil as of Jun. 2026.
Is Panacea Biotec's Long-Term Debt too high?
Panacea Biotec's current Long-Term Debt is ₹0 Mil. Overall, Panacea Biotec has a GF Score™ of 59/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Panacea Biotec's Long-Term Debt compare to VRTX and REGN?
Panacea Biotec's Long-Term Debt of ₹0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Biotechnology company?
A good Long-Term Debt depends on the Biotechnology industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Panacea Biotec's current Long-Term Debt is ₹0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Panacea Biotec stock overvalued right now?
Based on GuruFocus' analysis, Panacea Biotec (BOM:531349) is currently considered Fairly Valued. The stock's GF Value™ is ₹403.16, compared to a current price of ₹402.75 — trading 0.1% below its estimated fair value. The current Long-Term Debt is ₹0 Mil. Panacea Biotec's overall GF Score™ is 59/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Panacea Biotec (BOM:531349), the current Long-Term Debt is ₹0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Panacea Biotec (BOM:531349) Overvalued in 2026?

Based on GuruFocus' analysis, Panacea Biotec stock appears to be undervalued. The current stock price of ₹402.75 is trading 0.1% below its estimated GF Value™ of ₹403.16. GuruFocus considers Panacea Biotec to be Fairly Valued.

Key valuation signals for BOM:531349:

  • Long-Term Debt: ₹0 Mil
  • GF Value™: ₹403.16 vs. price of ₹402.75 (0.1% below fair value)
  • GF Score™: 59/100

No single metric tells the full story. See the BOM:531349 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Panacea Biotec Business Description

Other Exchanges PANACEABIO:India
Address Mathura Road, B-1 Extension/G-3, Mohan Co-operative Industrial Estate, New Delhi, IND, 110044
Panacea Biotec Ltd is a Biotechnology company. It is engaged in the business of research, development, manufacturing, and marketing of branded pharmaceutical formulations, vaccines, and biopharmaceuticals. The company's operating segments include Vaccines, and Formulations. It generates maximum revenue from the Vaccines segment. The company product portfolio includes prescription products in niche therapeutic areas such as diabetes and cardiovascular management, oncology, nephrology and transplant management, osteoporosis management, gastro-intestinal care, pain management products, and pediatric immunization. The group has a business presence in India and Outside India.
59GF Score

Get the complete analysis for BOM:531349

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹402.75
Price
₹403.16
GF Value